Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs

Journal of Endocrinological Investigation

Volumn 36, Issue 1, 2013, Pages 38-43

  Wildemberg, L E A ^a   Neto, L V ^a   Costa, D F ^a   Nasciuti, L E ^a   Takiya, C M ^a   Alves, L M ^a   Rebora, A ^b   Minuto, F ^b   Ferone, D ^b   Gadelha, M R ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Acromegaly; Dopamine receptors; Immunohistochemistry; Somatostatin analogues; Somatostatin receptors

Indexed keywords

ANGIOPEPTIN; DOPAMINE 2 RECEPTOR; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR 2;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CONTROL; DRUG DOSE INCREASE; FEMALE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREOPERATIVE TREATMENT; PROTEIN EXPRESSION; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACROMEGALY; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CASE-CONTROL STUDIES; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMAN GROWTH HORMONE; HUMANS; IMMUNOENZYME TECHNIQUES; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PROGNOSIS; RECEPTORS, DOPAMINE; RECEPTORS, SOMATOSTATIN; YOUNG ADULT;

EID: 84873603331     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8305     Document Type: Article

References (37)

1. Melmed S, Colao A, Barkan A, et al; Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009, 94: 1509-17.
2. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005, 90: 4465-73.
3. Giustina A, Chanson P, Bronstein MD, et al; Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010, 95: 3141-8.
4. Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients-a clinical research center study. J Clin Endocrinol Metab 1995, 80: 2768-75.
5. Colao A, Ferone D, Lastoria S, et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 1996, 81: 2356-62.
6. Halah FP, Elias LL, Martinelli CE Jr, Castro M, Moreira AC. Usefulness of subcutaneous or long-acting octreotide as a predictive test and in the treatment of acromegaly. Arq Bras Endocrinol Metabol 2004, 48: 245-52.
7. Taboada GF, Donangelo I, Guimaraes RF, Silva Mde O, Fontes R and Gadelha MR. Acute test with subcutaneous octreotide as a predictor of the response to treatment with octreotide LAR. Arq Bras Endocrinol Metabol 2005, 49: 390-5.
8. Legovini P, De Menis E, Billeci D, Conti B, Zoli P, Conte N. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients. J Endocrinol Invest 1997, 20: 424-8.
9. Plöckinger U, Bäder M, Hopfenmüller W, Saeger W, Quabbe HJ. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology. Eur J Endocrinol 1997, 136: 369-76.
10. Barlier A, Gunz G, Zamora AJ, et al. Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. J Clin Endocrinol Metab 1998, 83: 1604-10.
11. Spada A, Arosio M, Bochicchio D, et al. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 1990, 71: 1421-6.
12. Taboada GF, Neto LV, Luque RM, et al. Impact of gsp oncogene on the mRNA content for somatostatin and dopamine receptors in human somatotropinomas. Neuroendocrinology 2011, 93: 40-7.
13. Taboada GF, Luque RM, Bastos W, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 2007, 156: 65-74.
14. Taboada GF, Luque RM, Neto LV, et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 2008, 158: 295-303.
15. Saveanu A, Gunz G, Dufour H, et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001, 86: 140-5.
16. Park C, Yang I, Woo J, et al. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Endocr J 2004, 51: 227-36.
17. Jaquet P, Saveanu A, Gunz G, et al. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 2000, 85: 781-92.
18. Vieira Neto L, Taboada GF, Gadelha MR. Somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide LAR responsiveness in acromegaly. Arq Bras Endocrinol Metabol 2008, 52: 1288-95.
19. Fougner SL, Borota OC, Berg JP, Hald JK, Ramm-Pettersen J, Bollerslev J. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf) 2008, 68: 458-65.
20. Ferone D, de Herder WW, Pivonello R, et al. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab 2008, 93: 1412-7.
21. Takei M, Suzuki M, Kajiya H, et al. Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide. Endocr Pathol 2007, 18: 208-16.
22. Resmini E, Dadati P, Ravetti JL, et al. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 2007, 92: 1592-9.
23. Plöckinger U, Albrecht S, Mawrin C, et al. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab 2008, 93: 1203-10.
24. Casarini AP, Jallad RS, Pinto EM, et al. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary 2009, 12: 297-303.
25. Saveanu A, Jaquet P, Brue T, Barlier A. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Mol Cell Endocrinol 2008, 286: 206-13.
26. Ferone D, Gatto F, Arvigo M, et al. The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol 2009, 42: 361-70.
27. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526-9.
28. Thodou E, Kontogeorgos G, Theodossiou D, Pateraki M. Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol 2006, 59: 274-9.
29. Wildemberg LE, Neto LV, Takiya CM, Alves LM, Gadelha MR. Low somatostatin receptor subtype 2 protein expression is a negative predictor of biochemical control with octreotide-LAR. Arq Bras Endocrinol Metab 2010, 54: S53.
30. Mercado M, Borges F, Bouterfa H, et al; SMS995B2401 Study Group. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol 2007, 66: 859-68.
31. Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, openlabel, multicentre study. Clin Endocrinol 2009, 70: 757-68.
32. Patel RC, Kumar U, Lamb DC, et al. Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc Natl Acad Sci U S A 2002, 99: 3294-9.
33. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of heterooligomers with enhanced functional activity. Science 2000, 288: 154-7.
34. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo-and heterodimers. J Biol Chem 2000, 275: 7862-9.
35. Zatelli MC, Piccin D, Tagliati F, et al. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro. J Mol Endocrinol 2005, 35: 333-41.
36. Arvigo M, Gatto F, Ruscica M, et al. Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. J Endocrinol 2010, 207: 309-17.
37. Neto LV, Machado Ede O, Luque RM, et al. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab 2009, 94: 1931-7.